.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Low-dose vaginal estrogen is an evidence-based option for genitourinary symptoms of menopause, including vaginal dryness, dyspareunia and some urinary symptoms. Compared with systemic estrogen therapy, local preparations produce much lower systemic exposure while directly treating the vaginal and lower urinary tract tissues affected by estrogen deficiency. For gynecologists, the treatment is particularly useful when symptoms are predominantly genitourinary rather than vasomotor. Counseling should address product selection, ongoing use and individual breast-cancer or thrombotic history. In women with a history of hormone-sensitive malignancy, treatment decisions should be coordinated with the relevant oncology team. The key clinical point is that genitourinary symptoms often require local therapy and may recur when treatment is stopped.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Low-dose vaginal estrogen is an evidence-based option for genitourinary symptoms of menopause, including vaginal dryness, dyspareunia and some urinary symptoms. Compared with systemic estrogen therapy, local preparations produce much lower systemic exposure while directly treating the vaginal and lower urinary tract tissues affected by estrogen deficiency. For gynecologists, the treatment is particularly useful when symptoms are predominantly genitourinary rather than vasomotor. Counseling should address product selection, ongoing use and individual breast-cancer or thrombotic history. In women with a history of hormone-sensitive malignancy, treatment decisions should be coordinated with the relevant oncology team. The key clinical point is that genitourinary symptoms often require local therapy and may recur when treatment is stopped.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
Last week
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
